FDA blesses combo use of GSK's Mekinist, Tafinlar in melanoma
This article was originally published in Scrip
Executive Summary
After having a banner year in 2013 – winning the most approvals in the US of new molecular entities (NMEs) –GlaxoSmithKline started out 2014 by gaining the FDA's blessing to market Mekinist (trametinib) and Tafinlar (dabrafenib) for use in combination to treat metastatic or unresectable melanoma.
You may also be interested in...
Keeping Track: Pre-Independence Day Fireworks Crackle At US FDA With Burst Of Approvals And Filings
The latest drug development news and highlights from our US FDA Performance Tracker.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.